- Subtitle:
- Conference abstract
- Abstract:
-
Background: In GEMINI 1, UC response to vedolizumab (VDZ) was 47% at Week 6 and 42% by Week 52. Our aim was to assess real-life outcomes for VDZ in UC. Methods: Data collected at 12 Australian (Aus), 1 UK and 2 Hong Kong (HK) centres, assessed response to VDZ at 3, 6, and 12 months using the Mayo Clinic Score (MCS, Aus/HK) or SCCAI and UCEIS (UK). Results: Two hundred and ninety-three patients (53% male, median age 38 years, 196 Aus, 93 UK, 4 HK) were assessed with similar age, disease locati...
Expand abstract - Publication status:
- Published
- Peer review status:
- Reviewed (other)
- Version:
- Accepted Manuscript
- Files:
-
-
(pdf, 113.5KB)
-
- Publisher copy:
- 10.1093/ecco-jcc/jjx180.698
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
- Publisher:
- Oxford University Press Publisher's website
- Volume:
- 12
- Issue:
- S1
- Pages:
- S395-S396
- Publication date:
- 2018-01-16
- Acceptance date:
- 2018-01-15
- DOI:
- EISSN:
-
1876-4479
- ISSN:
-
1873-9946
- Pubs id:
-
pubs:844107
- URN:
-
uri:ff30c8e4-428d-4fc2-a9cf-c926b1a79602
- UUID:
-
uuid:ff30c8e4-428d-4fc2-a9cf-c926b1a79602
- Local pid:
- pubs:844107
- Copyright holder:
- European Crohn’s and Colitis Organisation
- Copyright date:
- 2018
- Notes:
- Copyright © 2018 European Crohn’s and Colitis Organisation (ECCO). This is a conference abstract presented at the 13th Congress of ECCO – European Crohn’s and Colitis Organisation, 14-17 February 2018, Vienna, Austria. This is the accepted manuscript version of the abstract. The final version is available online from Oxford University Press at: https://doi.org/10.1093/ecco-jcc/jjx180.698
Conference item
P571 Vedolizumab (VDZ) real-world outcomes in ulcerative colitis (UC)
Actions
Access Document
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Bibliographic Details
Item Description
Terms of use
If you are the owner of this record, you can report an update to it here: Report update to this record